These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38344732)

  • 21. An integrated analysis of safety and tolerability of etelcalcetide in patients receiving hemodialysis with secondary hyperparathyroidism.
    Block GA; Chertow GM; Sullivan JT; Deng H; Mather O; Tomlin H; Serenko M
    PLoS One; 2019; 14(3):e0213774. PubMed ID: 30875390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics.
    Arenas MD; Rodelo-Haad C; de Mier MVP; Rodriguez M
    Clin Kidney J; 2021 Mar; 14(3):840-846. PubMed ID: 33777366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of dialysate Ca concentrations on the therapeutic effects of etelcalcetide with concomitant drugs in patients with secondary hyperparathyroidism.
    Shigematsu T; Fukagawa M; Yokoyama K; Akiba T; Fujii A; Shinoda A; Akizawa T
    Nephrology (Carlton); 2020 Aug; 25(8):634-643. PubMed ID: 31765028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients.
    Fukagawa M; Yokoyama K; Shigematsu T; Akiba T; Fujii A; Kuramoto T; Odani M; Akizawa T;
    Nephrol Dial Transplant; 2017 Oct; 32(10):1723-1730. PubMed ID: 28057872
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug disposition model of radiolabeled etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism on hemodialysis.
    Wu L; Melhem M; Subramanian R; Wu B
    J Pharmacokinet Pharmacodyn; 2017 Feb; 44(1):43-53. PubMed ID: 28063122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Evaluation of Calcimimetics for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease, in an Italian Clinical Setting.
    Perrone V; Dovizio M; Veronesi C; Andretta M; Bartolini F; Cavaliere A; Ferrante F; Lupi A; Pagliaro R; Pagnotta R; Palcic S; Re D; Ubertazzo L; Vercellone A; Degli Esposti L
    Healthcare (Basel); 2022 Apr; 10(4):. PubMed ID: 35455886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of Etelcalcetide for the Treatment of Secondary Hyperparathyroidism in Patients with CKD-MBD on Hemodialysis: A Nephrology Nursing Perspective.
    Hain D; Tomlin H; Gibson C
    Nephrol Nurs J; 2019; 46(3):315-290. PubMed ID: 31199098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etelcalcetide (AMG 416), a peptide agonist of the calcium-sensing receptor, preserved cortical bone structure and bone strength in subtotal nephrectomized rats with established secondary hyperparathyroidism.
    Li X; Yu L; Asuncion F; Grisanti M; Alexander S; Hensley K; Han CY; Niu QT; Dwyer D; Villasenor K; Stolina M; Dean C; Ominsky MS; Ke HZ; Tomlinson JE; Richards WG
    Bone; 2017 Dec; 105():163-172. PubMed ID: 28867373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
    Bernardor J; De Mul A; Bacchetta J; Schmitt CP
    Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Single- and Multiple-Dose, Multicenter Study of Etelcalcetide in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism.
    Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Fujii A; Yamauchi A; Odani M; Akizawa T;
    Kidney Int Rep; 2017 Jul; 2(4):634-644. PubMed ID: 29142982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Etelcalcetide Is Effective at All Levels of Severity of Secondary Hyperparathyroidism in Hemodialysis Patients.
    Cunningham J; Block GA; Chertow GM; Cooper K; Evenepoel P; Iles J; Sun Y; Ureña-Torres P; Bushinsky DA
    Kidney Int Rep; 2019 Jul; 4(7):987-994. PubMed ID: 31317120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism.
    Yu L; Tomlinson JE; Alexander ST; Hensley K; Han CY; Dwyer D; Stolina M; Dean C; Goodman WG; Richards WG; Li X
    Calcif Tissue Int; 2017 Dec; 101(6):641-653. PubMed ID: 29038882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New scenarios in secondary hyperparathyroidism: etelcalcetide. Position paper of working group on CKD-MBD of the Italian Society of Nephrology.
    Bellasi A; Cozzolino M; Malberti F; Cancarini G; Esposito C; Guastoni CM; Ondei P; Pontoriero G; Teatini U; Vezzoli G; Pasquali M; Messa P; Locatelli F
    J Nephrol; 2020 Apr; 33(2):211-221. PubMed ID: 31853791
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Etelcalcetide controls secondary hyperparathyroidism and raises sclerostin levels in hemodialysis patients previously uncontrolled with cinacalcet.
    Pereira LAL; Meng C; Amoedo MAG; Mendes MTSCPF; Marques MAMP; Frazão JMMD; Weigert ALL
    Nefrologia (Engl Ed); 2023; 43(2):197-203. PubMed ID: 36437202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation.
    D'Marco L; Checa-Ros A; Gamero D; Soto C; Salazar J; Nava M; Bermúdez V; Dapena F
    Healthcare (Basel); 2022 Dec; 11(1):. PubMed ID: 36611532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan.
    Yokoyama K; Fukagawa M; Shigematsu T; Akiba T; Yoshikawa K; Tsuchiya A; Kuwabara M; Akizawa T
    Clin Exp Nephrol; 2021 Jan; 25(1):66-79. PubMed ID: 32816132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism.
    Bushinsky DA; Chertow GM; Cheng S; Deng H; Kopyt N; Martin KJ; Rastogi A; Ureña-Torres P; Vervloet M; Block GA
    Nephrol Dial Transplant; 2020 Oct; 35(10):1769-1778. PubMed ID: 30859218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1, single-dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of etelcalcetide in pediatric patients with secondary hyperparathyroidism receiving hemodialysis.
    Sohn W; Salusky IB; Schmitt CP; Taylan C; Walle JV; Ngang J; Yan L; Kroenke M; Warady BA
    Pediatr Nephrol; 2021 Jan; 36(1):133-142. PubMed ID: 32647975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Severe hypercalcaemia early after kidney transplantation in two patients with severe secondary hyperparathyroidism previously treated with etelcalcetide.
    Dachy G; Pochet JM; Labriola L; Buemi A; Gillion V; Jadoul M; Kanaan N; Devresse A
    Clin Kidney J; 2021 Aug; 14(8):1977-1979. PubMed ID: 34345422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Etelcalcetide for the treatment of secondary hyperparathyroidism.
    Hamano N; Komaba H; Fukagawa M
    Expert Opin Pharmacother; 2017 Apr; 18(5):529-534. PubMed ID: 28277829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.